CN1102044C - Draco nis sanguis micro sponge agent and its preparing technology - Google Patents
Draco nis sanguis micro sponge agent and its preparing technology Download PDFInfo
- Publication number
- CN1102044C CN1102044C CN00113055A CN00113055A CN1102044C CN 1102044 C CN1102044 C CN 1102044C CN 00113055 A CN00113055 A CN 00113055A CN 00113055 A CN00113055 A CN 00113055A CN 1102044 C CN1102044 C CN 1102044C
- Authority
- CN
- China
- Prior art keywords
- stirring
- sanguis
- draco
- nis
- gelatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to an oral taking medicine dragons blood micro sponge agent and a preparation process thereof. Which belongs to the technical field of medicine. The product can be a dragon blood micro spongy agent containing gelatin, and is preferably made by the following method: the gelatin is dissolved in added water, the gelatin is stirred at the temperature of 35 to 45 DEG C and is foamed, and formaldehyde solution is continuously added in the agitation process; when a lot of even and fine foam is genrated, dragon blood is added; after the mixture is stirred to be even, the mixture is separately filled in a container whose wall surface is provided with micropores and is frozen; the spongy agent which is frozen well is dried and pulverized. The present invention provides a new medicine having the advantages of conspicuous curative effect, convenient use and enhanced affinity of the dragon blood and the water, and can treat gastrointestinal hemorrhage and stomach intestine canker. Simultaneously, a spongy mass also has hemostasis action and hemostasis can be carried out in a synergistic way.
Description
The invention belongs to technical field of pharmaceuticals, be specially a kind of oral medicine Draco nis sanguis micro sponge agent and preparation technology thereof.
Sanguis Draxonis has another name called Sanguis Draxonis, and the former plant of extracting Sanguis Draxonis has that the Fructus Crotonis of the dracaena of dragons and snakes the orchid family, palmaceous Daemonorops, Euphorbiaceae belongs to, kind of plant surplus pulse family amboyna ten in belonging to.As the history in existing more than 1500 year of rare Chinese medicine, the beginning is stated from the Lei Gong's Treatise on Preparation and Broiling of Materia Medica in Northern and Southern Dynasties' epoch in China.Sanguis Draxonis sweet in the mouth, salty, flat, GUIXIN, Liver Channel, the effect of the pain relieving of tool clots absorbing, hemostasis, promoting tissue regeneration and ulcer healing is mainly used in traumatic hemorrhage, ulcer being unable to heal, traumatic injury, the stasis of blood disease such as have a pain that stagnates.Sanguis Draxonis tool heparin resistance can be used for hemostasis.There are two kinds of factors of blood coagulation and haemolysis among the normal human, are in the dynamic equilibrium, when this balance is destroyed, thrombosis or hemorrhage two kinds of pathological phenomenons will occur.Sanguis Draxonis can recover its physiological equilibrium, therefore can be used for invigorating blood circulation and stopping blooding.Sanguis Draxonis also has the microcirculatory function in the lesion of improvement in addition, makes local organization recover normal mechanism, increases local blood fortune and resistance against diseases, has quickened the epithelial tissue growth, impels wound to heal rapidly.The product of Sanguis Draxonis only has ordinary powder and capsule formulation in the market, can not satisfy clinical requirement far away.Gastrointestinal hemorrhage and gastroenteritic ulcer are common clinicals, but Sanguis Draxonis are not made this sick microsponge agent of treatment.
The purpose of this invention is to provide a kind of oral medicine for the treatment of gastrointestinal hemorrhage and gastroenteritic ulcer---Draco nis sanguis micro sponge agent and preparation technology thereof, to satisfy doctors and patients' needs.
Product of the present invention is characterised in that the microsponge agent that contains the active constituents of medicine Sanguis Draxonis for a kind of.Product of the present invention can be the Draco nis sanguis micro sponge agent that contains gelatin.Said Draco nis sanguis micro sponge agent can be a powder, also can further be packaged into hard capsule or be processed into other adoptable dosage forms.
Product of the present invention is preferably the Draco nis sanguis micro sponge agent of making by the following method: gelatin is dissolved in water, make foaming 35-45 ℃ of stirring, constantly add formalin in the stirring, when producing the foam of a large amount of uniform and smooth, add Sanguis Draxonis, being sub-packed in wall after stirring has in the container of micropore freezingly, will freeze good sponginum drying, pulverizes.
The Draco nis sanguis micro sponge agent of best product of the present invention for making by the following method: the gelatin of getting 20-2000 part weight adds water continuous stirring in water-bath makes dissolving, make foaming 36-42 ℃ of stirring, the formalin that constantly adds 3-6% concentration in the stirring, when producing the foam of a large amount of uniform and smooth, add the Sanguis Draxonis of 100 parts of weight, be sub-packed in after stirring in the burlap box, the refrigerator and cooled of putting into subzero 6-18 ℃ is frozen, to freeze good sponginum and put into blast chamber and make it dry, pulverize, sieve.
The preparation technology of product of the present invention is: gelatin is dissolved in water, make foaming 35-45 ℃ of stirring, constantly add formalin in the stirring, when producing the foam of a large amount of uniform and smooth, add Sanguis Draxonis, being sub-packed in wall after stirring has in the container of micropore freezingly, will freeze good sponginum drying, pulverizes.
The preparation technology of products perfection of the present invention is: the gelatin of getting 20-2000 part weight adds water continuous stirring in water-bath makes dissolving, make foaming 36-42 ℃ of stirring, the formalin that constantly adds 3-6% concentration in the stirring, when producing the foam of a large amount of uniform and smooth, add the Sanguis Draxonis of 100 parts of weight, be sub-packed in after stirring in the box that fabric makes, the refrigerator and cooled of putting into subzero 6-18 ℃ is frozen, to freeze good sponginum and put into blast chamber and make it dry, pulverize, sieve.The box that said fabric is made is preferably the burlap box.
Clinical practice and curative effect
Clinical patients 30 examples of picked at random gastrorrhagia and gastric ulcer are with this sponginum treatment, 1 week of the course of treatment, every day 3 times, each 1.Effective percentage reaches 93% as a result, and cure rate reaches 70%.
The invention has the beneficial effects as follows the treatment gastrointestinal hemorrhage that provide a kind of evident in efficacy, easy to use and the new drug of gastroenteritic ulcer disease.Draco nis sanguis micro sponge agent can improve the affinity of Sanguis Draxonis and water, and spongy body also has anastalsis simultaneously, can stop blooding with Sanguis Draxonis is collaborative.If further make capsule, can avoid the powder taking dose inaccurate, shortcomings such as dysphagia.
Embodiment 1: get gelatin 20g, add water 180ml continuous stirring in water-bath and make dissolving, make foaming with the eggbeater stirring, constantly add 4.4% formalin 17ml in the stirring at 38 ℃, when producing the foam of a large amount of uniform and smooth, add the 20g Sanguis Draxonis, be sub-packed in after stirring in the burlap box, the refrigerator and cooled of putting into-10 ℃ is frozen, to freeze good sponginum puts into blast chamber and makes it dry, pulverize, cross sieve No. 2, encapsulated.
Instrument: JB50D type reinforcement electric blender (Shanghai Sample Model Factory).
Medicine and reagent: Sanguis Draxonis is that tropical plants garden, Xishuangbanna pharmaceutical factory produces; Gelatin is medicinal specification.The Yunnan Sanguis Draxonis is the Dracaena cochinchinensis resin, therefrom separablely goes out 5 aromatic compounds, to some antibacterial tool antibacterial activities.
Differentiate and check:
Character: the product content thing is blood red sponginum.
Differentiate: get sponginum 0.2g and put into the 20ml test tube, add 75% ethanol 10ml, close plug, jolting 10 minutes, filter, filtrate volatilizes, and as test sample liquid, other gets Sanguis Draxonis control medicinal material 0.1g behind the residue usefulness 10ml ether dissolution, shine medical material solution in pairs with legal system, according to thin layer chromatography (appendix VIB) test, get each 10-20 μ l of need testing solution, control medicinal material solution and Dracoalban's reference substance solution, put respectively on same silica gel g thin-layer plate, with chloroform-methanol (95: 5) is developing solvent, launch, take out, dry.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on show identical orange speckle; With the corresponding position of reference substance chromatograph on show identical orange speckle.
Check:
Weight differential: get 20 of capsules, the accurate title, decided gross weight, and it is heavy to obtain average particle, fixed each capsules of accurate again title, and the result should meet the pharmacopeia pertinent regulations.
Disintegration: according to relevant requirements under the pharmacopeia capsule, should be up to specification.
Colophonium: get this product 5g, put in the tool plug test tube, add petroleum ether (60-90 ℃) 10ml, jolting 10 minutes filters, and gets filtrate 5ml, adds the about 0.5% Schweinfurt green solution 5ml of new preparation, and that standing demix after the jolting, petroleum ether layer must not show is light blue, blueness or aeruginous.
A study on the stability: (being lower than 25 ℃) placed in the cool dark place of Draco nis sanguis micro sponge agent room temperature, investigated by under differentiating and check respectively at 3,6,9,12 months, as a result no change.
Embodiment 2: get gelatin 6g, add water 54ml continuous stirring in water-bath and make dissolving, make foaming with the eggbeater stirring, constantly add 4.4% formalin 5ml in the stirring at 38 ℃, when producing the foam of a large amount of uniform and smooth, add the 20g Sanguis Draxonis, be sub-packed in after stirring in the burlap box, the refrigerator and cooled of putting into-10 ℃ is frozen, to freeze good sponginum puts into blast chamber and makes it dry, pulverize, cross sieve No. 2, encapsulated.All the other are with embodiment 1.
Embodiment 3: get gelatin 300g, add water 2700ml continuous stirring in water-bath and make dissolving, make foaming with the eggbeater stirring, constantly add 4.4% formalin 255ml in the stirring at 38 ℃, when producing the foam of a large amount of uniform and smooth, add the 20g Sanguis Draxonis, be sub-packed in after stirring in the burlap box, the refrigerator and cooled of putting into-10 ℃ is frozen, to freeze good sponginum puts into blast chamber and makes it dry, pulverize, cross sieve No. 2, encapsulated.All the other are with embodiment 1.
Embodiment 1-3 products obtained therefrom all can be realized purpose of the present invention.
Above embodiment is only for the present invention is further illustrated, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
Claims (7)
1, a kind of Draco nis sanguis micro sponge agent is characterized in that the active constituents of medicine that contains is a Sanguis Draxonis, and the treatment effective dose of Sanguis Draxonis is 4.76%～83.3% of a Draco nis sanguis micro sponge agent gross weight.
2,, it is characterized in that for containing the Draco nis sanguis micro sponge agent of gelatin as the said Draco nis sanguis micro sponge agent of claim 1.
3, as the said Draco nis sanguis micro sponge agent of claim 2, it is characterized in that the product for making by the following method: gelatin is dissolved in water, make foaming 35-45 ℃ of stirring, constantly add formalin in the stirring, when producing the foam of a large amount of uniform and smooth, add Sanguis Draxonis, being sub-packed in wall after stirring has in the container of micropore freezing, to freeze good sponginum drying, pulverize.
4, as the said Draco nis sanguis micro sponge agent of claim 3, it is characterized in that the product for making by the following method: the gelatin of getting 20-2000 part weight adds water continuous stirring in water-bath makes dissolving, make foaming 36-42 ℃ of stirring, the formalin that constantly adds 3-6% concentration in the stirring, when producing the foam of a large amount of uniform and smooth, the Sanguis Draxonis that adds 100 parts of weight, be sub-packed in after stirring in the burlap box, the refrigerator and cooled of putting into subzero 6-18 ℃ is frozen, to freeze good sponginum puts into blast chamber and makes it dry, pulverize, sieve.
5, a kind of Draco nis sanguis micro sponge agent preparation technology, it is characterized in that: gelatin is dissolved in water, make foaming 35-45 ℃ of stirring, constantly add formalin in the stirring, when producing the foam of a large amount of uniform and smooth, add Sanguis Draxonis, being sub-packed in wall after stirring has in the container of micropore freezing, to freeze good sponginum drying, pulverize.
6, as the said Draco nis sanguis micro sponge agent preparation technology of claim 5, it is characterized in that: the gelatin of getting 20-2000 part weight adds water continuous stirring in water-bath makes dissolving, make foaming 36-42 ℃ of stirring, the formalin that constantly adds 3-6% concentration in the stirring, when producing the foam of a large amount of uniform and smooth, the Sanguis Draxonis that adds 100 parts of weight, be sub-packed in after stirring in the box that fabric makes, the refrigerator and cooled of putting into subzero 6-18 ℃ is frozen, to freeze good sponginum puts into blast chamber and makes it dry, pulverize, sieve.
7,, it is characterized in that the box that said fabric is made is the burlap box as the said Draco nis sanguis micro sponge agent preparation technology of claim 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00113055A CN1102044C (en) | 2000-06-22 | 2000-06-22 | Draco nis sanguis micro sponge agent and its preparing technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00113055A CN1102044C (en) | 2000-06-22 | 2000-06-22 | Draco nis sanguis micro sponge agent and its preparing technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1279982A CN1279982A (en) | 2001-01-17 |
| CN1102044C true CN1102044C (en) | 2003-02-26 |
Family
ID=4582874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00113055A Expired - Fee Related CN1102044C (en) | 2000-06-22 | 2000-06-22 | Draco nis sanguis micro sponge agent and its preparing technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1102044C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103330678B (en) * | 2013-06-05 | 2014-12-17 | 南方医科大学 | Paeonol tiny sponge preparation and preparation method thereof |
| CN108721685B (en) * | 2017-12-11 | 2021-01-19 | 北京化工大学 | Preparation method of self-foaming hemostatic biological sponge |
| CN108892954B (en) * | 2018-07-18 | 2021-04-30 | 广州迈普再生医学科技股份有限公司 | Tissue scaffold with double-layer structure and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106278A (en) * | 1994-02-02 | 1995-08-09 | 梁俊成 | Ulcer powder |
-
2000
- 2000-06-22 CN CN00113055A patent/CN1102044C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106278A (en) * | 1994-02-02 | 1995-08-09 | 梁俊成 | Ulcer powder |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1279982A (en) | 2001-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861287B (en) | Chinese medicinal composition for treating damp-heat invasion blood stasis diabetic foot and preparation method thereof | |
| CN104274546B (en) | A kind of external medicine composition, traditional Chinese medicine for outer use and its preparation method and application | |
| CN102579560A (en) | Preparation method of Chinese angelica and astragalus mongholicus mixture aqueous extract, as well as application in intervening in pulmonary fibrosis | |
| CN108619473A (en) | A kind of Chinese medicine fuming-lotion for treating diabete peripheral herve pathology | |
| CN1102044C (en) | Draco nis sanguis micro sponge agent and its preparing technology | |
| CN102772712A (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN101564465B (en) | Chinese medicinal composition for nourishing blood, benefiting vital energy, regulating menstruation and dissipating cold | |
| KR20040060808A (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| KR102613167B1 (en) | Traditional Chinese herbal compositions and their methods and applications | |
| CN114452354A (en) | Traditional Chinese medicine composition for wound, extract and application thereof | |
| CN113144114A (en) | Traditional Chinese medicine composition for reducing blood fat and preparation method thereof | |
| CN1961933A (en) | Hyperosteogeny-resisting formulation for treating orthopaedics disease, preparation method and quality control method thereof | |
| CN1961912A (en) | Chinese medicinal composition containing pain-easing bleeding-stopping functions | |
| CN101716253A (en) | Chinese medicinal preparation containing panax notoginseng, and preparation method thereof | |
| CN107050393A (en) | Numbness of relaxing dispersing paste and preparation method and application | |
| CN116650477B (en) | Pharmaceutical composition containing ozagrel sodium for resisting platelet aggregation and preparation method thereof | |
| CN1120710C (en) | Homorrholdal suppository of draconis sanguis and its producing method | |
| CN108420877A (en) | It is a kind of to treat traumatic injury and swelling and pain relieving Chinese medicine preparation | |
| CN108815268A (en) | A kind of external application promotees the Chinese medicine ointment formulation and preparation method thereof of union of wounded skin | |
| CN104587047B (en) | A kind of Chinese medicine composition for being used to treat cardiovascular and cerebrovascular disease | |
| CN108743800A (en) | A kind of traditional Chinese medicine powder for treating cardiovascular and cerebrovascular | |
| CN112870250B (en) | Composition for preventing and treating organ fibrosis and application and preparation thereof | |
| CN115212253B (en) | Chinese herbal compound preparation for treating hepatic fibrosis and preparation method and application thereof | |
| JP6725955B1 (en) | Zhuang pharmaceutical composition for blood supplementation and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |